|
Synonyms: eflapegrastim-xnst | HM-10460A | HM10460A | rolontis | Rolvedon® | SPI-2012 | SPI2012
eflapegrastim is an approved drug (FDA (2022))
Compound class:
Peptide or derivative
Comment: Eflapegrastim (SPI-2012) is a long-acting, human granulocyte colony-stimulating factor (G-CSF) recombinant peptide. Structurally it consists of a recombinant G-CSF (1-174) peptide monomer and an IgG4 Fc dimer, that are joined by a PEG-derived linker molecule. G-CSF stimulates neutrophil progenitor proliferation and differentiation, a molecular mechanism that is exploited to reduce the incidence and severity of chemotherapy-induced neutropenia. The Fc fragment increases the drug's half-life (reduces clearance) and overall efficacy by improving uptake into the bone marrow via binding to Fc receptors on the endothelial cells [1].
|
Classification  |
|
| Compound class | Peptide or derivative |
| Approved drug? | Yes (FDA (2022)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9918 | eflapegrastim |
| Synonyms |
| eflapegrastim-xnst | HM-10460A | HM10460A | rolontis | Rolvedon® | SPI-2012 | SPI2012 |
| Database Links |
|
| GtoPdb PubChem SID | 472319302 |
| Search PubMed clinical trials | eflapegrastim |
| Search PubMed titles | eflapegrastim |
| Search PubMed titles/abstracts | eflapegrastim |
